Share
437 Posts.
lightbulb Created with Sketch. 211
clock Created with Sketch. 27/12/23
19:05
Share
Originally posted by JB1975:
↑
Site visits and initiations are being reported - patients being treated are not being reported yet . You cannot treat a patient with the protocol (I've doubts about a protocol that isn't explicit about the control to split breakdown between treatment and control arms because it feels like preserving wiggle room for a rejig in the event that the control arm is hard to recruit into) unless you have a location that agrees to treat them with that protocol. trial designs such that the experts report back to shareholders. (This probably is not industry standard - it seems that current industry standard is that boards and so called science officers bs the shareholders with smoke and mirrors and various forms of non commital obfuscation. This( an independent appraisal of trial design could) keeps some stuff that should be commercially in confidence not generally disclosed (the experts could agree not to act on the information and sign contracts to that effect with appropriate penalty clauses) but at the same time doesn't leave shareholders bs-ed year after year. As deadlines get stung out and surprise surprise unfortunately more dilution is needed to do the little that was previously promised before.
Expand
"When I think about both Cynata and Mesoblast I think maybe what is needed is independent expert evaluations of the trial designs such that the experts report back to shareholders."
(20min delay)